Cargando…

The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing

INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Fur...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Sean, Visgauss, Julia, Kerr, David, Helmkamp, Joshua, Said, Nicholas, Vinson, Emily, O'Donnell, Patrick, Li, Xuechan, Jung, Sin-Ho, Cardona, Diana, Eward, William, Brigman, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884200/
https://www.ncbi.nlm.nih.gov/pubmed/29755284
http://dx.doi.org/10.1155/2018/1901896
_version_ 1783311778746204160
author Ryan, Sean
Visgauss, Julia
Kerr, David
Helmkamp, Joshua
Said, Nicholas
Vinson, Emily
O'Donnell, Patrick
Li, Xuechan
Jung, Sin-Ho
Cardona, Diana
Eward, William
Brigman, Brian
author_facet Ryan, Sean
Visgauss, Julia
Kerr, David
Helmkamp, Joshua
Said, Nicholas
Vinson, Emily
O'Donnell, Patrick
Li, Xuechan
Jung, Sin-Ho
Cardona, Diana
Eward, William
Brigman, Brian
author_sort Ryan, Sean
collection PubMed
description INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in the literature. METHODS: We retrospectively collected 49 patients with lipomas or WDLs utilizing MDM2 for pathologic diagnosis. Four expert readers interpreted each patient's MRI independently and provided a diagnosis. Additionally, a formula based on imaging characteristics (i.e. tumor depth, diameter, presence of septa, and internal cystic change) was used to predict the pathologic diagnosis. The accuracy and reliability of imaging-based diagnoses were then analyzed in comparison to the MDM2 pathologic diagnoses. RESULTS: The accuracy of MRI readers was 73.5% (95% CI 61–86%) with substantial interobserver agreement (κ=0.7022). The formula had an accuracy of 71%, which was not significantly different from the readers (p=0.71). The formula and expert observers had similar sensitivity (83% versus 83%) and specificity (64.5% versus 67.7%; p=0.659) for detecting WDLs. CONCLUSION: The accuracy of both our readers and the formula suggests that MRI remains unreliable for distinguishing between lipoma and WDLs.
format Online
Article
Text
id pubmed-5884200
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58842002018-05-13 The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing Ryan, Sean Visgauss, Julia Kerr, David Helmkamp, Joshua Said, Nicholas Vinson, Emily O'Donnell, Patrick Li, Xuechan Jung, Sin-Ho Cardona, Diana Eward, William Brigman, Brian Sarcoma Research Article INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in the literature. METHODS: We retrospectively collected 49 patients with lipomas or WDLs utilizing MDM2 for pathologic diagnosis. Four expert readers interpreted each patient's MRI independently and provided a diagnosis. Additionally, a formula based on imaging characteristics (i.e. tumor depth, diameter, presence of septa, and internal cystic change) was used to predict the pathologic diagnosis. The accuracy and reliability of imaging-based diagnoses were then analyzed in comparison to the MDM2 pathologic diagnoses. RESULTS: The accuracy of MRI readers was 73.5% (95% CI 61–86%) with substantial interobserver agreement (κ=0.7022). The formula had an accuracy of 71%, which was not significantly different from the readers (p=0.71). The formula and expert observers had similar sensitivity (83% versus 83%) and specificity (64.5% versus 67.7%; p=0.659) for detecting WDLs. CONCLUSION: The accuracy of both our readers and the formula suggests that MRI remains unreliable for distinguishing between lipoma and WDLs. Hindawi 2018-03-19 /pmc/articles/PMC5884200/ /pubmed/29755284 http://dx.doi.org/10.1155/2018/1901896 Text en Copyright © 2018 Sean Ryan et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ryan, Sean
Visgauss, Julia
Kerr, David
Helmkamp, Joshua
Said, Nicholas
Vinson, Emily
O'Donnell, Patrick
Li, Xuechan
Jung, Sin-Ho
Cardona, Diana
Eward, William
Brigman, Brian
The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
title The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
title_full The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
title_fullStr The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
title_full_unstemmed The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
title_short The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing
title_sort value of mri in distinguishing subtypes of lipomatous extremity tumors needs reassessment in the era of mdm2 and cdk4 testing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884200/
https://www.ncbi.nlm.nih.gov/pubmed/29755284
http://dx.doi.org/10.1155/2018/1901896
work_keys_str_mv AT ryansean thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT visgaussjulia thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT kerrdavid thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT helmkampjoshua thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT saidnicholas thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT vinsonemily thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT odonnellpatrick thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT lixuechan thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT jungsinho thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT cardonadiana thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT ewardwilliam thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT brigmanbrian thevalueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT ryansean valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT visgaussjulia valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT kerrdavid valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT helmkampjoshua valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT saidnicholas valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT vinsonemily valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT odonnellpatrick valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT lixuechan valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT jungsinho valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT cardonadiana valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT ewardwilliam valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing
AT brigmanbrian valueofmriindistinguishingsubtypesoflipomatousextremitytumorsneedsreassessmentintheeraofmdm2andcdk4testing